Tom Grossmann, professor of Biomimetic Chemistry at VU Amsterdam, has been awarded a Proof of Concept grant by the European Research Council (ERC), for the proCOLON project. He plans to use this €150,000 research grant for the development of new therapeutics for colorectal cancer.
With more than 1.9 million new cases and 935,000 related deaths in 2020, colorectal cancer is the third most common cancer in men and the second in women. While surgery is the main treatment option for lower grade colorectal cancer, patients whose tumors cannot be surgically removed are treated with chemotherapy. These therapies are associated with severe drawbacks, such as unpredictable resistance. A team of scientists from VU Amsterdam and Amsterdam UMC will therefore work on developing new therapies to treat this form of cancer.
Error in the Wnt signalling pathway
Hyperactivation of the Wnt signalling pathway is associated with various forms of cancer. In colorectal cancer, this signaling pathway is hyperactivated in 80% of all cases. The protein beta-catenin is a component of the Wnt signaling pathway and activates T-cell factors, which ultimately stimulate cell growth and spread. Therefore, inhibition of beta-catenin is considered an interesting therapeutic approach. However, there are no approved drugs that inhibit beta-catenin so far.
Beta-catenin inhibitors
Grossmann and colleagues identified a family of peptidomimetics that bind beta-catenin and inhibit its interaction with the T-cell factors. For the first time, it was possible to obtain a crystal structure of a synthetic molecule bound to a therapeutically very attractive site on beta-catenin. In addition, they have confirmed cellular activity of these inhibitors, verifying the selective inhibition of the Wnt signalling pathway. According to Grossmann, these findings provide the ideal starting point for the development of new therapeutics for Wnt-dependent cancers, in particular for colorectal cancer.
Proof of Concept grants
The ERC has awarded a total of 166 researchers a Proof of Concept Grant. The funding will allow them to investigate whether they can commercialise their ideas. The grants are part of the EU’s research and innovation programme, Horizon Europe.
In the race to a sustainable and healthy future, the benefits of biotech innovations are key. Both biotech academics and entrepreneurs must continue to turn knowledge into social and commercial successes. Nettie Buitelaar, Biotech Booster ‘s CEO, answers five questions in order to tell us how to boost new biotech innovations. The Biotech Booster programme […]
NewsInnoseis recently marked a significant milestone – a decade of pioneering work in seismic sensing. The company, a spin-off of VU and the National Institute for Subatomic Physics, Nikhef, uses precision motion sensing for seismic and guidance applications. We sat down with CEO Mark Beker and CTO Jo van den Brand to learn more about […]
NewsThe Dutch company NoWa Kitchen presented its newest kitchen featuring only bio-based materials and a sustainable cradle-to-cradle design. A key enabler for the kitchen are plant-based polymers and materials brought to market by the University of Amsterdam’s spin-off company Plantics, stemming from a discovery made by chemists at the Van ‘t Hoff Institute for Molecular […]
News